Table 3 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer | Synapse
October 2, 2025
Table 3 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Key Points
Over 20% of patients experienced treatment-emergent adverse events during the trial.
The safety analysis involved 41 patients receiving the combination therapy with hormone receptor-positive, HER2-negative advanced breast cancer.
Combination therapy with gedatolisib, palbociclib, and letrozole may offer a novel treatment strategy.
Findings may support changes in therapy approaches for patients with advanced breast cancer.
Abstract
TEAEs (of any cause, occurring in >20% of patients in the safety analysis set; N = 41).